SGMO | Sangamo Therapeutics
Category: Biotechnology company
Quick infos Headquarters: Richmond, California, United States Trade prices Volume: Market Cap: 627.82M Prev closed: Open: 6.01 High: 6.07 Low: 5.75 52 week low: 5.1 52 week high: 13.93 Dividends: No Dividends Next ER: November 3, 2022
About the Company Sangamo Therapeutics, Inc. is an American biotechnology company based in Richmond, California. It applies cell and gene therapy to combat haemophilia and other genetic diseases.
Earnings History Date EPS / Forecast Revenue / Forecast March 2, 2023 November 3, 2022 -0.34 / -0.355526.46M / 26.59MAugust 4, 2022 -0.29 / -0.352729.38M / 24.63MBeat! May 5, 2022 -0.3 / -0.311128.23M / 27.29MBeat! February 24, 2022 -0.26 / -0.345528M / 26.82MBeat! view more
Historical Data Date Price Open High Low Vol Change ER Aug 16, 2022 6.09 6.34 6.34
5.99
1.36M -4.69% Aug 15, 2022 6.39 6.25 6.42
6.19
2.01M 0.95% Aug 12, 2022 6.33 5.85 6.39
5.77
1.46M 8.76% Aug 11, 2022 5.82 5.93 6.14
5.76
2.20M -0.51% Aug 10, 2022 5.85 5.40 5.87
5.28
2.50M 11.64% Aug 9, 2022 5.24 5.20 5.30
5.05
1.37M -0.95% Aug 8, 2022 5.29 5.23 5.36
5.12
1.48M 1.73% Aug 5, 2022 5.20 4.69 5.24
4.60
1.40M 9.01% Aug 4, 2022 4.77 4.78 4.81
4.62
2.14M -0.63% Aug 3, 2022 4.80 4.51 4.94
4.50
2.02M 8.11% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company ISIN: US8006771062 CUSIP: 800677106 Founded:1995 Employees:131 News
Sangamo Therapeutics (NASDAQ:SGMO) investors are sitting on a loss of 78% if they invested five years ago finance.yahoo.com Dec 6, 2022 6:02 am Sangamo Therapeutics GAAP EPS of -$0.34 beats by $0.02, revenue of $26.5M misses by $0.29M seekingalpha.com Nov 4, 2022 4:02 am
Sangamo Therapeutics (SGMO) Reports Q3 Loss, Lags Revenue Estimates finance.yahoo.com Nov 3, 2022 5:55 pm Sangamo Therapeutics Q3 2022 Earnings Preview seekingalpha.com Nov 3, 2022 5:35 am
Sangamo Therapeutics Announces Third Quarter 2022 Conference Call and Webcast finance.yahoo.com Oct 27, 2022 4:15 pm
Sangamo Touts Additional Positive Data For Fabry Gene Therapy Candidate finance.yahoo.com Oct 12, 2022 8:55 am
Pfizer Resumes Dosing In Phase 3 Hemophilia Gene Therapy Trial Six Months After FDA Lifts Clinical Hold finance.yahoo.com Sep 23, 2022 12:02 pm Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy seekingalpha.com Sep 23, 2022 5:38 am
Sangamo's Fabry Disease Gene Therapy Continues To Show Encouraging Safety Profile finance.yahoo.com Aug 30, 2022 8:50 am
Does Sangamo (SGMO) Have the Potential to Rally 122% as Wall Street Analysts Expect? finance.yahoo.com Aug 29, 2022 9:55 am
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com Aug 4, 2022 5:45 pm
Sangamo Therapeutics Announces Second Quarter 2022 Conference Call and Webcast finance.yahoo.com Jul 28, 2022 4:15 pm SGMO, IMGN and BPOP are among after hour movers seekingalpha.com Jul 20, 2022 5:25 am
Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans? finance.yahoo.com Jul 18, 2022 9:21 am Sangamo Therapeutics begun at neutral at Wedbush on 'frontrunner' Fabry candidate seekingalpha.com Jun 14, 2022 5:44 am Bluebird Bio drives gene therapy stocks higher after FDA review seekingalpha.com Jun 8, 2022 3:59 am
Why Did Sangamo Stock Jump 20% Today? finance.yahoo.com Jun 2, 2022 5:20 pm
Sangamo Therapeutics Announces First Quarter 2021 Conference Call and Webcast finance.yahoo.com Jun 2, 2022 4:15 pm Sangamo gene therapy for Fabry disease shows promise in phase 1/2 trial seekingalpha.com Aug 30, 2022 6:52 pm Biotech in recovery; but Piper Sandler cites negative fund flows seekingalpha.com Aug 22, 2022 This company doesn't provide a dividend.
Key Persons CEO : Alexander Macrae, PhD Talk about Sangamo Therapeutics below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Homepage: sangamo.com Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon In the world of investing, slow and steady wins the race. With this mantra in mind, trusted author and finance guru Eric Tyson is back with the latest edition of the #1 bestselling book, Investing For Dummies, to help you achieve your investment goals.
